IFNG and neoplasm: A pan-tumor T-cell-inflamed gene expression profile (GEP) consisting of 18 IFN-γ-responsive genes was validated and confirmed to predict response to ICB therapy in pretreatment tumor specimens from nine types of cancers, including melanoma17.